Genome editing advances drug discovery in biomedical research.
Functional genomics study reveals a potential approach for tackling glioblastoma, pancreatic cancer and other tumors.
Industry labs find that, contrary to earlier evidence, KRAS-driven tumors are not addicted to autophagy.
An investigational treatment for an uncommon immunodeficiency disease races into clinical studies.
Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.
This site is intended for a global audience.